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  The hepatitis B virus (HBV) infects more than 260 million people globally, with increasing incidence, especial-
ly in developing countries. Despite antiviral therapies, HBV-related end-stage liver disease remains one of the 
most important indications for liver transplantation worldwide. Although new available treatments have im-
proved the outcome of patients with both compensated and decompensated liver disease in some specific 
clinical settings as acute-on-chronic liver failure mortality is still high. Moreover, the incidence of HBV-related 
hepatocellular carcinoma (HCC) seems to be increasing and represents a major challenge for the transplant 
team. In the post-transplant setting, combination of anti-HBV immunoglobulins and oral nucleos(t)ides pro-
vided significant improvement on graft and patient survival. Furthermore, recent data suggested the possibil-
ity of personalized therapeutic algorithms based on pre and post-transplant viral and host risk factors. Finally, 
liver grafts from HBV core antibody (anti-HBc) positive or hepatitis B surface antigen (HBsAg) donors can be 
safely used in order to expand the donor pool, considering adequate allocation and tailored prophylaxis after 
LT. In this review we have focused on the evolution of antiviral therapy for HBV, highlighting useful informa-
tion to aid the transplant hepatologist in clinical practice.
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Background
Despite massive vaccination campaigns, chronic hepatitis B 
(CHB) remains one of the most important causes of liver dis-
ease worldwide. Approximately 350–400 million people are 
chronic HBV surface antigen (HBsAg) carriers [1]. The spectrum 
of disease and natural history of chronic HBV infection is pro-
tean, ranging from inactive carrier state to progressive chronic 
hepatitis (CHB), which may lead to cirrhosis and hepatocellular 
carcinoma (HCC) [2–4]. Longitudinal studies of untreated pa-
tients with CHB indicate that the 5-year cumulative incidence 
of cirrhosis ranges from 8% to 20%. This wide range is due to 
the fact that different factors (host or virus-related, co-infec-
tion with HCV, HDV or HIV viruses, metabolic syndrome, and 
alcohol) can affect the natural course of HBV infection [2–8]. 
In this group of patients, the 5-year cumulative incidence of 
hepatic decompensation is approximately 20% [2–4,9–11]. 
Decompensation represents a major change in the natural 
history of liver disease, being associated with poor prognosis 
(14–35% probability of survival at 5 years) [1,2,9–11]. Finally, it 
should be pointed out that the annual incidence of HBV-related 
HCC is particularly high, ranging from 2% to 5% [11]. HBV is 
responsible for a mortality rate of 2.7 and 3.5 persons per 100 
000 inhabitants per year [12]. Furthermore, HBV-related cir-
rhosis with or without HCC still represents one of the major 
indications for liver transplantation (LT) [13]. In the last de-
cades, the introduction of new antiviral therapies has dramat-
ically changed the clinical practice both in the pre- and post-
transplant setting and, nowadays, from the therapeutic point 
of view, management of HBV infection can be split up into 2 
major chapters: before and after LT.
Antiviral Therapy in HBV-Related Cirrhosis
Compensated disease
The goal of therapy for CHB is to improve survival and health 
related quality of life (HRQOL) by preventing progression to cir-
rhosis, decompensated cirrhosis, end-stage liver disease (ESLD), 
HCC and death. This goal can be achieved if HBV replication is 
persistently suppressed. However, chronic HBV infection can-
not be completely eradicated due to the persistence of cova-
lently closed circular DNA (ccc-DNA) in the nucleus of infected 
hepatocytes and to the HBV genome integration. Therefore, 2 
major clinical implications should be highlighted. First, the risk 
of HBV reactivation [14–16] implies the need for long-life an-
tiviral therapy when eradication is not feasible. Second, there 
will never be no risk at all of HCC development [17,18]; there-
fore, long-term HCC surveillance is mandatory [19].
The first issue is when to start antiviral therapy in this popu-
lation. Both patients with compensated and decompensated 
cirrhosis must be considered for treatment, regardless of HBV 
DNA detectability and/or ALT activity [20]. In this difficult-to-
treat population, significant clinical improvement can be ob-
tained with control of viral replication [21–23]. However, antivi-
ral therapy may not be enough to rescue some decompensated 
patients with very advanced liver disease who should be con-
sidered for LT.
The second question is which antiviral therapy should be pre-
ferred in case of advanced liver disease. Currently, there are 2 
different treatment strategies: treatment of limited duration 
with PEG-interferon (PEG-IFN) or long-term treatment with 
nucleos(t)ide analogues (NUCs). Five oral NUCs have been li-
censed for the treatment of CHB: 3 nucleoside [lamivudine 
(LAM), telbivudine (TBV), entecavir (ETV)] [1,2] and 2 nucleo-
tide [adefovir dipivoxil (ADF) and tenofovir disoproxil fuma-
rate (TDF)] analogues [20].
PEG-IFN-based antiviral therapy in patients with cirrhosis may 
increase the risk of bacterial infection and hepatic decompen-
sation [24]. However, PEG-IFN regimens can be used for the 
treatment of well-compensated cirrhosis [25]. LAM (100 mg/
day) was the first NUC approved for treatment of CHB and sev-
eral randomized controlled trials confirmed its efficacy, show-
ing stabilization or even improvement of liver function [26]. 
However, long-term LAM monotherapy is unavoidably asso-
ciated with progressively increasing rates of viral resistance 
due to YMDD mutations (15–25% at year 1, 65–80% at year 
5) [27]. Given that, international guidelines do not recom-
mend LAM monotherapy in patients with HBV cirrhosis [20]. 
Moreover, high baseline HBV DNA levels are associated with 
higher risk of LAM resistance, at least in HbeAg-positive pa-
tients, as shown by Lau et al. [28].
ADF (10 mg/day) was the second NUC approved. However, as 
well as for LAM, clinicians must be aware of the risk of resis-
tance during long-term therapy in naive patients (29% at 5 
years) [29]. Since then, high costs and risk of renal toxicity [30] 
caused it to be largely replaced. TBV (600 mg) is a potent nu-
cleoside analogue; however, its use in CHB monotherapy is also 
associated with YMDD mutations [31], and its use in mono-
therapy remains a matter of debate. Risk of resistance with 
ETV/TDF (0.5 mg) is minimal [32]. Thus, both of them are cur-
rently considered the treatment of choice in patients with both 
compensated and decompensated liver disease [20]. Previous 
history should also be evaluated. In fact, in patients with LAM 
resistance, ETV monotherapy should be avoided since the risk 
of resistance rises to 50% after 5 years of ETV treatment [33]. 
Finally, close monitoring of HBV DNA levels every 3 months, at 
least during the first year of therapy and until HBV DNA unde-
tectability, remains mandatory because flare-ups of hepatitis 
B, requiring urgent management, may occur [34]. Finally, in our 
clinical practice in patients with compensated liver cirrhosis 
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and no active HBV replication (HBV DNA-negative), we do not 
usually suggest NUCs-based antiviral therapy (given the mech-
anism of action of this category of drugs).
Decompensated disease
Patients with decompensated cirrhosis still represent a major 
challenge for hepatologists. Since the management of antiviral 
therapy is complex and these patients may be candidates for 
LT, they should be treated in specialized liver units. As previ-
ously mentioned, antiviral treatment is indicated irrespective 
of HBV DNA levels. PEG-IFN is contraindicated in this setting, 
thus second-generation NUCs (ETV/TDF) should be preferred. 
Recent studies have shown that ETV/TDF drugs are effective 
and also generally safe in these patients [21–23]. Suppression 
of HBV replication may lead to clinical improvement over a 
period of 3–6 months, and then LT may be avoided. In such 
cases, life-long treatment is needed [20]. Some patients with 
advanced liver disease may experience a disease progression 
beyond the “point of no return”, and may not benefit, thus 
requiring LT [35]. In that situation, treatment with NUCs in-
ducing HBV DNA undetectability at LT will decrease the risk 
of HBV recurrence in the graft [32].
Regarding NUCs adverse effects, lactic acidosis has been re-
ported in small groups of patients with advanced liver dis-
ease (MELD score >20)treated with ETV [36]. Therefore, clinical 
and laboratory parameters should be closely monitored [22].
HBV-Related Acute-on-Chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is an increasingly recog-
nized entity encompassing an acute deterioration of liver func-
tion in patients with cirrhosis, either secondary to superim-
posed liver injury (i.e., active alcoholism, acute reactivation of 
HBV, and HDV superinfection) or due to extrahepatic precipi-
tating factors such as infection culminating in multi-organ dys-
function [37]. In 40% of cases, no precipitating events can be 
identified [38]. The prevalence of ACLF in the CANONIC Study 
was 30% (20% at admission and 10% during hospitalization), 
being particularly prevalent in alcoholic and HBV-related cir-
rhosis [38]. It is estimated that approximately 70% of liver fail-
ure in China is caused by HBV [39]. HBV infection is a dynam-
ic state of interactions among HBV, hepatocytes, and immune 
cells of the host. Accordingly, hepatitis activity with alanine 
aminotransferase (ALT) elevation and episodic abrupt rise of 
ALT, so-called acute exacerbation or hepatitis flare, may oc-
cur spontaneously [40] during or after antiviral therapy or in 
the setting of immunosuppression and/or chemotherapy [41]. 
HBV flares occur during the HBeAg-positive immune clearance 
phase [40,42–44]or in the HBeAg-negative reactive phase, but 
less frequently [45,46]. The clinical spectrum of HBV flare is 
wide and varies from totally asymptomatic to a condition of 
decompensation [45–48], which can culminate in ACLF [49–
51]. LT is the only definitive treatment for ACLF in patients who 
did not respond to supportive measures [52,53], with a 5-year 
survival rate of around 61% [54].
Antiviral therapy in HBV-related ACLF
As previously mentioned, the efficacy of NUCs has been largely 
confirmed for treatment of CHB [20]. However, whether NUCs 
would be effective for HBV-related ACLF remains controver-
sial. The aim of antiviral treatment for ACLF-HBV is to reduce 
viral load in order to favor reduction in hepatocyte death and 
improve survival outcomes by prevention of decompensation. 
Some studies suggested that pretreatment HBV DNA load and 
its rapid reduction improved outcomes in HBV-related ACLF. 
More particularly, mortality of patients receiving NUCs was 
significantly lower than in the placebo group when antiviral 
therapy was started early [55].
Several studies considered the use of NUCs in patients with 
HBV-related ACLF. Chan et al. [56] evaluated the role of LAM 
in treatment of severe HBV flare leading to ACLF in 28 pa-
tients vs. 18 controls. The authors concluded that LAM ad-
ministration was not associated with any survival benefit. The 
same results were described by Tsubota et al. [57] in 25 pa-
tients with spontaneous HBV flare treated with LAM. Wong et 
al. [58] treated 45 patients with severe flare and 31 controls 
with LAM for a median of 2.8 (range 1.0–7.1) years and 3.8 
(range 3.5–8.4) years, respectively. They found that patients 
with severe acute exacerbation had higher HBeAg seroconver-
sion rates and lower risk of virological breakthrough. However, 
33% of patients with severe acute exacerbation still devel-
oped LAM resistance and virological breakthrough by 5 years. 
In a second cohort of 60 consecutive HBV-related ACLF pa-
tients treated with LAM, Chen et al. [59] concluded that LAM 
may prevent death if therapy was started early (before se-
rum bilirubin levels rose over 20 mg/dL). Sun et al. [60], an-
alyzing the factors which could affect prognosis, and found 
that cumulative survival rates of patients in the LAM group 
were higher than those of the control group. In the study by 
Tsang [61], 24 patients treated with LAM were subsequent-
ly divided into 2 groups: Group A including patients who sur-
vived (33%) and group B including 13 patients who died and 
3 patients who underwent LT (67%). Full HBeAg seroconver-
sion was documented in 6 out of 8 (75%) patients after a few 
months of LAM treatment. However, HBeAg reverted to pos-
itive in 4 patients after the end of therapy, leading to recur-
rent hepatitis. Nevertheless, the authors concluded that LAM 
may be useful in treating patients with HBV-related ACLF. It 
should be noted that only 33% of enrolled patients survived 
without LT. Why was LAM so ineffective in treating this popu-
lation? Factors other than viral replication have a great impact 
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on the prognosis. Livers of these patients have already under-
gone massive or sub-massive hepatic necrosis. Therefore, sup-
pressing viral replication at this late stage seemed ineffective, 
as the major determinants for prognosis are liver regenera-
tion and rapid cessation of ongoing inflammation. Neither of 
these factors are directly dependent on HBV. Moreover, in re-
cent years, LAM therapy for ACLF-HBV has become less ap-
pealing due to drug resistance.
Data regarding the use of ADF for ACLF-HBV are very 
scant [62,63]. In 2 case reports, ADF failed as rescue therapy 
of LAM resistance after jaundice and development of liver fail-
ure. Adefovir has a relatively weak antiviral activity. Therefore, 
ADF use as a first-line drug in the treatment of acute severe 
exacerbation seems unfavorable.
Chen et al. administered ETV to 55 patients with severe acute 
exacerbation of HBV, comparing them with 74 patients who were 
not treated with any NUC. ETV was capable of a great reduction 
of HBV replication; however, the MELD score and liver function 
tests (albumin, bilirubin, and prothrombin time) showed no sig-
nificant change. Therefore, the authors concluded that short-
term suppression of HBV replication may not reduce the pro-
gression of liver failure [64]. In 2013, Lai et al. [65] analyzed the 
data from 182 HBeAg-negative Chinese patients with ACLF (93 
treated with ETV and 89 with LAM). HBV DNA levels decreased 
within 3 months in both groups (P<0.05), regardless of MELD 
score before treatment. More importantly, 3-month mortality 
was similar between groups. Given that, they concluded that 
ETV and LAM are equally effective. Liu et al. [66] performed a 
similar study, showing no significant differences between vi-
rological, biochemical, and clinical outcome in 2 groups of pa-
tients treated with ETV vs. LAM [36]. In a more recent study by 
Chen et al. [67], both the safety and efficacy of ETV and TBV 
were evaluated. Twenty-one consecutive patients with ACLF-
HBV were treated with either ETV or TBV. During the course, 
deterioration of estimated glomerular filtration rate was sig-
nificant in the entecavir-treated group (P=0.028) but not in tel-
bivudine-treated patients (p=0.8). Furthermore, patients treat-
ed with TBV had a significant increase in serum a-fetoprotein 
(27.9–191.9 ng/mL, P=0.046) in the first 2 weeks, whereas the 
corresponding increase was not found in those treated with 
ETV (P=0.139) [67]. The pros and cons of LAM vs. ETV in de-
compensated or severe acute exacerbation of CHB show that 
ETV seems more effective in promoting faster viral load reduc-
tion, albeit its hepatic and extrahepatic adverse effects [68[.
Garg et al. [69] randomized consecutive patients with ACLF 
due to spontaneous reactivation of CHB to receive either TDF 
or placebo, with a primary endpoint of 3-month survival. They 
showed a rapid (>2 log within 2 weeks) decrease in HBV DNA, 
and reported that TDF-based therapy significantly improved 
survival in HBV DNA-related ACLF.
Yu et al. [70] recently conducted a meta-analysis of prospec-
tive and retrospective studies to examine the efficacy and safe-
ty of NUCs in treating HBV-related ACLF. All the ACLF patients 
included in the studies met the APASL diagnostic criteria [71]. 
Five eligible studies, 2 RCTs [69,72] and 3 retrospective stud-
ies [59,60,73], were identified. Antiviral treatment with NUCs 
led to significant reduction of HBV DNA [HBV DNA reduction 
>2 log: 70.4 vs. 29%, RR=2.29, 95%CI (1.49, 3.53), P<0.01] and 
incidence of HBV reactivation [1.80 vs. 18.4%, RR=0.11, 95%CI 
(0.03, 0.43), p<0.01]. Three-month mortality was significantly 
lower in patients receiving NUCs [44.8 vs. 73.3%, RR=0.68, 95%CI 
(0.54, 0.84), p<0.01] as compared to no treatment. However, 3 
studies compared LAM vs. ETV as rescue therapy, suggesting no 
significant difference in the prognosis [36.4 vs. 40.5%, RR=0.77, 
95%CI (0.45, 1.32), p=0.35]. Given these data, NUCs treatment 
(LAM with the same result of ETV) seems to reduce short-term 
mortality as well as reactivation of HBV-related ACLF patients. 
It should be noted that even in the treatment group, only pa-
tients with rapid decline in HBV DNA had a better prognosis 
[60,69]. Thus, viral factors may participate to the pathogene-
sis of the severe hepatic necro-inflammation, and subsequent-
ly to decompensation. Therefore, appropriate antiviral therapy 
might prevent, or at least slow, the progression of necro-in-
flammation and allow hepatic regeneration. However, compa-
rable efficacy was found between ETV and LAM. Nevertheless, 
it might be possible that the difference between ETV and LAM 
in suppressing HBV replication was not large enough to affect 
the prognosis of this difficult-to-treat population.
Other treatments have been evaluated in the setting of HBV-
related ACLF (e.g., corticosteroids, granulocyte colony-stimulat-
ing factors, artificial liver support systems, immune regulatory 
therapy, and stem cell therapy) [74]. Some of these therapeu-
tic approaches have been shown to potentially improve liver 
function and increase patient survival, but most of the stud-
ies were not randomized or controlled. Moreover, these kinds 
of treatment are still experimental and not available in clini-
cal practice. Finally, since patients with ACLF are very challeng-
ing and require rapid multidisciplinary evaluation, they should 
be referred to a tertiary care center when LT is feasible [75].
HBV-Related Acute Liver Failure
HBV is an important cause of acute liver failure (ALF) world-
wide. The prognosis is quite poor, with reported LT-free sur-
vival ranging from 26% to 53% [76]. Despite recent advances 
in antiviral agents, there is no definitive evidence that anti-
viral therapy can modify the natural history of the disease.
To date, no placebo-controlled trials have been published in the 
setting of HBV-related ALF. Some case series suggested lower 
mortality in patients with ALF treated with antiviral therapy 
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compared to patients without treatment. However, it should 
be stressed that most of these studies recruited patients be-
fore the development of grade 3 or 4 hepatic encephalopathy.
In the multicenter study by Tillmann et al. [77], patients with 
severe acute or fulminant hepatitis B were treated with LAM in 
an attempt to prevent HBV reinfection after potential LT. Since 
September 2000, 17 patients with HBV infection were treated 
with 100 or 150 mg LAM daily once there was evidence for a 
severe course as indicated by an INR >2.0. Fourteen of the 17 
patients (82.4%) survived with full recovery without LT. All these 
14 individuals cleared HBsAg on LAM within 6 months. Twelve 
patients recovered quickly, as indicated by a normalized pro-
thrombin time within 1 week, while 2 patients had a more pro-
longed course. None of the patients showed adverse events. 
Three patients requiring LT despite LAM therapy had more ad-
vanced disease at admission. The LAM-treated patients had sig-
nificantly higher LT-free survival (82.4 vs. 20%) if compared with 
a historic cohort (P<0.001). The authors concluded that LAM 
seemed safe in patients with severe HBV-related ALF, leading 
to fast recovery and a potential prevention of liver failure and 
LT when administered early enough. However, the sample size 
seems too small for this conclusion. Moreover, the comparison 
with the historical control group could lead to several biases. 
Finally, the definition of ALF was based on prolonged INR and 
not on clinical features (e.g., severe hepatic encephalopathy).
In contrast, in the study by Dao et al. [78], which only includ-
ed patients with ALF defined by the presence of both enceph-
alopathy and INR >1.5, no beneficial effect of NUCs therapy 
was described in those with HBV-related ALF. The authors per-
formed a retrospective analysis of the outcome in 85 patients 
with HBV-related ALF, 43 of whom had received NUCs treat-
ment. Patients were enrolled in 23 centers between 1998 and 
2008. No significant differences were found at the baseline be-
tween treated and untreated groups. Median duration of NUCs 
treatment was 6 (range: 1–21) days. Interestingly, overall surviv-
al in the NUCs-treated and NUCs-untreated groups were 61% 
and 64%, respectively (p=0.72). Similarly, rates of transplant-
free survival were 21% and 36% in the treated and untreated 
groups, respectively, p=0.42. Furthermore, multivariate analysis 
revealed absence of NUCs as a predictor of survival [odds ra-
tio (OR) 4.4, 95% CI 1.1–18.1, p=0.041], as well as hepatic en-
cephalopathy grade I or II [OR 14.4, 95% CI 3.3–62.8, p<0.0001], 
and prolonged prothrombin time [OR 0.59, 95% CI 0.39–0.89, 
p<0.012]. Given these results, patients who are admitted with 
established HBV-ALF seem not to benefit from viral suppres-
sion using NUCs. Finally, Kumar et al. [79] performed a prospec-
tive randomized study showing no clinical benefit of LAM in 
acute hepatitis B, even though the decline of serum HBV DNA 
was faster. Patients with serum bilirubin of more than 5 mg/
dL were randomized to receive either 100 mg of LAM daily for 
3 months (group 1, n=31) or placebo (group 2, n=40). Patients 
were considered to have severe acute hepatitis B if they ful-
filled 2 of 3 criteria: (1) hepatic encephalopathy; (2) serum bili-
rubin ³10.0 mg/dL; and (3) INR ³1.6. At week 4, HBV DNA levels 
were significantly lower (P=0.037) in group 1 (median: 3.6721 
log copies/mL) than in group 2 (median: 4.2721 log copies/mL), 
whereas the improvement in serum bilirubin, ALT, and INR val-
ues was similar in the 2 groups. Twenty-two patients (71%) in 
group 1 and 25 patients (62.5%) in group 2 had severe acute 
hepatitis B. After 12 and 18 months, 93.5% and 92.5%, respec-
tively, of patients in the LAM group and 96.7% and 97.5%, re-
spectively, of patients in the placebo group lost HBsAg. There 
were no deaths in either group, so it is still uncertain wheth-
er these data can be generalized to patients with HBV-related 
ALF. One of the possible reasons of this clinical finding may be 
the rapid disease evolution. Blocking the viral replication in this 
clinical scenario may not be sufficient to stop massive necro-
inflammation induced by the immune activation. However, de-
spite the lack of benefit, NUCs therapy should be still at least 
be considered for LT candidates since viral suppression is im-
portant to prevent recurrence after grafting [80]. Considering 
the conflicting results and insufficient data, prospective ran-
domized controlled trials are necessary to assess the role of 
antiviral therapy in HBV-related ALF. To date, since there is not 
enough evidence that antiviral therapy or artificial liver support 
devices can improve patient survival, LT should still be consid-
ered as the only effective treatment option that can alter the 
grave prognosis of HBV-related ALF [75].
Recurrence of HBV Infection After LT
Recurrence of HBV infection after LT was considered a ma-
jor problem in the past because this risk was higher for HBV-
related cirrhosis than for HBV-related ALF. However, newly 
available weapons led to a significant improvement in graft 
and patient survival after LT for HBV in recent decades. Data 
retrieved from the ELTR registry [13] showed a 1-, 3-, 5-, and 
10-year graft survival of 83%, 77%, 74%, and 67%, respec-
tively, being significantly better than for HCV related cirrho-
sis (each p<0.001). Furthermore, short-term survival at 1 and 
3 years after LT after the start of the 21st century was signifi-
cantly higher compared to the previous decade (p<0.001), con-
firming the improvement in prognosis.
If untreated, recurrence after LT is almost universal, with rap-
idly progressive hepatitis that jeopardizes long-term patient 
and allograft survival.
Recurrence is firstly characterized by serum HBsAg and HBV 
DNA reappearance, followed by biochemical, histological, and 
clinical evidence of liver disease. Nonetheless, the definition 
of clinical recurrence after LT is somewhat controversial, be-
cause cases with detectable HBsAg, with undetectable HBV 
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DNA, normal liver enzymes, and no clinical manifestations of 
HBV recurrence may not have any clinical impact on long-term 
graft and patient survival [81].
A landmark multicenter study published in 1993 by Samuel et 
al. investigated risk factors for recurrence among 201 LT re-
cipients with HBV-related cirrhosis from 17 centers in Europe. 
They found in multivariate analysis that HBV DNA negativiza-
tion before LT (P<0.05) was associated with reduced risk of 
HBV recurrence. Thus, the number of patients with HBV DNA 
positivity at LT rapidly decreased over time (from 81.2% be-
fore 1995 to 51% in 2006–2010), although no significant differ-
ence was found in terms of patient and graft survival (p=0.79 
and p=0.88, respectively) [13]. Other factors associated with 
reduced risk of recurrence were HDV co-infection and ALF.
Other studies identified the protective role played by HDV in 
prevention of HBV recurrence after LT, because HDV exerts a 
suppressive effect on HBV replication after LT. Regarding HBV-
related ALF, the second group at lower risk of HBV recurrence, 
some authors asserted that the acute and massive necrosis 
secondary to fulminant infection can led to a natural clear-
ance of the viral load [82,83].
HBIg for HBV prophylaxis after LT
Initially, prophylaxis against HBV reinfection was successfully 
performed with anti-HBV immunoglobulins (HBIg), as shown 
by Samuel et al. [83] in 1993. HBIg may help the immune sys-
tem to protect the graft through binding to circulating viri-
ons, blocking the HBV receptor, and inducing lysis of infect-
ed cells by antibody-dependent cell-mediated cytotoxicity. 
The authors demonstrated a significant reduction of reinfec-
tion (from 75% to 33%) and an increase of mid-term survival 
(from 54% to 83%) after LT.
NUCs for HBV prophylaxis after LT
For the second time, the use of LAM opened a new chapter 
in the history of prophylaxis. In 1996 Grellier [84] showed 
that mono-prophylaxis with LAM before and after LT provid-
ed good short-term outcomes, with 9 out of 12 patients HBV 
DNA-negative within 6 months after LT. However, subsequent 
studies revealed a significant relapse due to LAM mutation; 
Chan [85] evaluated 20 LT recipients receiving LAM mono-pro-
phylaxis after LT for a median time of 2 years, and demonstrat-
ed a cumulative probability of developing mutations equal to 
34%. Thus, this treatment strategy is considered suboptimal, 
especially when using LAM mono-prophylaxis.
In the last decade, new-generation NUCs (ETV and TDF) have 
been tested as mono-prophylaxis in the setting of LT. Fung et 
al. [86] evaluated 80 consecutive LT recipients with previous 
chronic HBV liver disease, of which 41% received a DDLT and 
74% had detectable HBV DNA at the time of LT. The authors 
demonstrated that after a median follow-up of 26 months with 
ETV mono-prophylaxis, 8 patients did not achieve HbsAg se-
ro-clearance, while 10 experienced reappearance of HBsAg af-
ter initial sero-clearance; these 18 patients had higher HBsAg 
levels at the time of transplantation (868.95 vs. 415.10 U/mL, 
respectively; p=0.03), but only 1 patient had HBV DNA posi-
tivization. The same group [87] confirmed that mono-prophy-
laxis with high genetic barrier NUCs was safe in another study 
comprising 362 patients (38.4% having chronic HBV liver dis-
ease), of whom 142 were treated with ETV and 176 with LAM. 
Type of antiviral therapy (LAM vs. ETV), indication to LT (HCC 
vs. decompensated liver disease), and high viral load at LT 
were significant factors associated with virological rebound in 
multivariate analysis. More recently, Fernandez et al. [88] pro-
spectively enrolled 58 LT recipients who were mainly at low-
er risk of reinfection (ALF, HDV co-infection). After 12 months 
of combined NUCs/HBIg therapy, they were converted to TDF 
or ETV mono-prophylaxis; 5 patients (8.6%) developed HBsAg 
detectability, without HBV DNA reappearance.
Thus, ETV and TDF should be the first-line options when a mo-
no-prophylaxis would be adopted; for patients with known LAM 
resistance, TDF should be the treatment of choice.
Combination therapy
NUCs act directly by reducing viral load in the liver and extrahe-
patic sites. They determine a synergistic activity between HBIg 
and NUCs, because reduction of viral load can prevent satura-
tion of HBIg binding sites, and, conversely, HBIg reduces viral 
mutation [89]. At present, combination with NUCs and HBIg is 
considered the treatment of choice for prophylaxis of HBV re-
infection, since the risk of graft infection is less than 10% [75].
These data came from high-quality studies. A meta-analy-
sis comparing 10 studies, published by Katz et al. [90], dem-
onstrated that combination therapy was significantly better 
than HBIg monotherapy in preventing reinfection (6.2% vs. 
21%; RR=0.28; 95%CI: 0.12–0.66) and in reducing mortality 
(RR=0.44; 95% CI: 0.25–0.77).
Another systematic review aiming to assess any difference be-
tween high-barrier NUCs mono-prophylaxis and combination 
therapy [91] revealed that HBV recurrence was observed signif-
icantly less frequently using the latter strategy [26% (29/112) 
vs. 5.9% (109/1834), p<0.0001].
More recently, Wang et al. [92] performed a systematic review 
of 1484 patients from 19 studies, and demonstrated that com-
bined treatment reduced HBV recurrence (RR=0.16; 95%CI: 
0.12–0.20 p<0.001) and improved early survival (RR=0.08; 
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95%CI: 0.01–0.15; p=0.03). Interestingly, the authors showed 
that combination therapy was more effective only in the sub-
group with HBV DNA detectable before LT (p<0.001; RD=0.42; 
95%CI: 0.32–0.52), highlighting the importance of pre-LT viral 
load, also suggested by the abovementioned study by Fung [87].
Combination prophylaxis: Pros and cons.
In recent years, several factors (e.g., high-barriers NUCs and 
increasing survival rates, but also costs, treatment adherence, 
recipients aging, and comorbidities) led hepatologists to look 
for personalized prophylaxis regimens, which should be simul-
taneously effective and cost-saving (Table 1).
Regarding costs, combination therapy with high-dose HBIg 
costs over $100 000/patient in the first year after LT [93], sug-
gesting that this long-life therapy could not be affordable for 
all the heterogeneous healthcare systems worldwide.
Considering adherence, Chang et al. [94] demonstrated that 
non-compliance to HBIg was 14% in a small cohort of LT pa-
tients, even though anti-HBs titers were satisfactorily achieved. 
Adherence represents a main goal for LT recipients, indepen-
dent of etiologies [95].
Different routes of HBIg administration have been proposed 
to maximize compliance (self-made, home treatment subcuta-
neous route [96]), and quality of life. Franciosi et al. [97] vali-
dated a specific questionnaire for testing HRQOL among HBIg 
users. Intra-muscle administration provided better scores on 
the flexibility (81.5±21.4 vs. 73.1±24.2, P=0.01) and negative 
feelings scales (90.1±17.3 vs. 85.4±20.7, P=0.04).
On the other hand, long-term NUCs mono-prophylaxis raised 
some concerns in the setting of LT, mainly due to the possibil-
ity of renal dysfunction. Between 30% and 80% of LT recipi-
ents develop chronic kidney disease stage 3–4 within the first 
10 years post-LT. It can be due to pre-transplant injuries, ar-
terial vasoconstriction due to CNIs, recurrence of hepatitis C, 
diabetes, and/or metabolic syndrome. Chronic renal disease 
is associated with a statistically significant increased risk of 
mortality in the early and late post-LT course [75].
Even though both first- and second-generation NUCs can cause 
renal tubular dysfunction [98], a single-center observational 
study [99] did not show significant differences in renal impair-
ment between LT recipients treated with HBIg mono-prophylax-
is vs. combined prophylaxis (eGFR66.2±25 vs. 66.2±18 ml/min; 
p=0.29). However, the association between NUCs and renal dys-
function should be better evaluated with large-cohort studies, 
as well as in the long term after LT.
Personalized algorithms for prophylaxis
In recent years, personalized algorithms for prophylaxis of HBV 
reactivation, balancing risk factors for recurrence and patients’ 
comorbidities, have been proposed.
In a relatively small number of patients (n=102) followed for a 
median of 24 months [91], Cholongitas et al. confirmed that the 
use of ETV/TDF prophylaxis after HBIG discontinuation seemed 
not to be inferior to the combination of NUCs plus HBIg (3.9% 
vs. 1.0%, p=0.17), but also not to be superior to the combina-
tion of HBIg and LAM, when the definition of HBV recurrence 
was based either on HBsAg (3.9% vs. 5.9%, p=0.52) or HBV 
DNA reappearance (0% vs. 3.8%, p=0.08). Tandoi et al. [100] 
proposed an HBIg minimization strategy based on the individ-
ual risk profile and on serological targets. In 35 LT recipients 
(51.4% with HDV co-infection), they used a specific NUCs plus 
HBIg schedule (10 000 IU during the LT operation and subse-
quently 5000 IU/day until HBsAg negativization and achieve-
ment of an HBsAb protective level >300 mIU/mL, and then 
pulses of 2500 only if HBsAb titer was <300 mIU/mL). After a 
median follow-up of 10.5 months, there was no recurrence, 
and they reported a correlation between quantitative HBsAg 
level at LT and HBIg administered in the first month after LT.
Similarly, Hu et al. [101] demonstrated that an on-demand 
HBIg schedule (adjusted for anti-HBs titer) plus ETV was ef-
fective in preventing HBV recurrence, which developed in only 
2/145 (1.37%) patients. Also, a strategy using early subcuta-
neous administration of HBIg seemed effective in preventing 
HBV recurrence. De Simone et al. [102] prospectively switched 
49 patients from i.v. to s.c. HBIg administration within 3 weeks 
after surgery (adjusted dose according to serum anti-HBs ti-
ters). All patients receiving combination therapy remained HBV 
DNA-ve (45/45), and only 1 adverse event (mild injection site 
hematoma) was assessed as treatment-related.
Lastly, vaccination after LT has been investigated as a poten-
tial tool for prophylaxis of HBV recurrence. In a pilot study, 
Sanchez Fueyo et al. [103] demonstrated that HBV vaccination 
after 1-year therapy with HBIg was useful and cost-effective in 
a small cohort of 16 selected recipients. However, long-term 
follow-up data evaluating this strategy among large cohorts 
of patients are still missing.
In our opinion, combination therapy of HBIg [at least for a 
fixed period (1-year)] and NUCs seems to be the safest post-
transplant approach. Furthermore, this should be limited to 
non-HCC patients with no risk factors for HBV recurrence af-
ter liver transplantation (i.e., HBV DNA-negative at time of liver 
transplant). However, mono-prophylaxis strategies with high-
barrier NUCs, eventually based on pre-transplant risk factors, 
should be adopted [75].
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Authors, year 
[Ref]
No. of patients Study design
Mean 
follow-up 
(months)
Endpoint Outcome
Yi, 2013 
[70]
29 HBIg + ETV for 5 
weeks, then ETV 
monotherapy
31 Recurrence (HBsAg +) Recurrence-free survival 
96.6% at 1 year
Teperman, 2013 
[113]
40
(19 TDF; 18 
combo)
combination for 
24 weeks, then 
randomization
18 Recurrence (HBsAg+) Recurrence-free survival 
100% in both groups
Gane, 2013 
[114]
26 ADF+LAM before LT. 
HBIg withdrawal 7 
days after LT
57 Recurrence (HBsAg +/HBV 
DNA –)
Recurrence-free survival 
100%
Saab, 2011 
[115]
61 HBIg + LAM for 
12 months after 
LT; then, 2 NUCs 
(nucleotide and 
nucleoside)
15 Recurrence (HBsAg +), with 
or without HBV DNA +
RFS 98.3% at 1 year
Kawagishi, 2010 
[116]
14 HBIg+ NUCs for 12 
months; then only 
NUCs
30 Recurrence (HBsAg +) 2 out 14 experienced 
recurrences
Yuefeng, 2011 
[117]
15 HBIg + LAM, then 
LAM alone
Range 
42 to 86 
months
Recurrence (HBsAg + and 
HBV DNA +)
2 out of 15 experienced 
recurrences (LAM 
resistance)
Angus, 2008 
[118]
34 (16 ADF; 
18 HBIg)
HBIg + LAM 12 
months after LT. 
Then, randomization 
to ADF/HBIg
54 Recurrence (HBsAg+) Recurrence: 1/16 vs. 0/18
Buti, 2007 
[119]
29 (20 LAM; 9 
LAM + HBIg)
HBIg + LAM for 
1 month; then, 
randomization to 
LAM with or without 
HBIg
83 Recurrence (HBsAg+) Recurrence: 3/20 vs. 1/14. 
The mean recurrence-free 
interval was 92.77 and 
92.16 months (P=ns)
Wong, 2007 
[120]
21 (15 HBIg 
+ NUCs; 6 
NUCs)
HBIg + NUCs for 
12 months, then 
randomization 
to NUCs with or 
without HBIg
40 Recurrence (HBsAg + or 
HBV DNA ³5 log 
copies/mL)
0/15 vs. 2/6 (both patients 
with LAM resistance)
Lenci, 2011 
[121]
30 
(undetectable 
intrahepatic 
total and ccc-
DNA at time 
of LT)
HBIg withdrawal 
and continued 
lamivudine with 
monthly HBsAg and 
HBV DNA monitoring 
and sequential liver 
biopsies. If confirmed 
intrahepatic total 
and ccc-DNA 
undetectability 24W 
after stopping HBIg, 
® LAM withdrawal 
29 Recurrence (HbsAg +) Five patients became 
HbsAg-positive: one early 
after HBIg withdrawal, the 
other 4 after HBIG and 
lamivudine withdrawal
Table 1. Clinical trials evaluating strategies for HBV prophylaxis after LT in the last 10 years.
639
Zanetto A. et al.: 
New perspectives on treatment of hepatitis B before and after liver transplantation
© Ann Transplant, 2016; 21: 632-643
REVIEW PAPER
Indexed in: [Science Citation Index Expanded] [Index Medicus/MEDLINE] 
[Chemical Abstracts] [Scopus]
HBV-HDV liver transplant recipients
HDV co-infection is a known risk factor for end-stage liver dis-
ease. Co-infection has remained a stable indication for LT in the 
last 2 decades, with a prevalence of 2% of all LT in Europe [104]. 
Analyzing data from the ELTR registry [13], HDV co-infection 
was associated with better short- and long-term patient sur-
vival vs. HBV mono-infection (1-, 5-, and 10-year survival: 92%, 
89%, 86%, and 83%,75%, 60%, respectively, each p<0.001). 
Encouraging data were also confirmed for grafts (1-, 5-, and 
10- year graft survival: 81%, 85%, 80%; 80%, 71%, 64%, re-
spectively, each P < 0.001). Better survival is presumably due 
to inhibition of the HBV replication cycle [105]. Since specific 
prophylaxis for HDV reinfection is not available, the most ef-
fective strategy to prevent HDV reinfection is the standard HBV 
prophylaxis with HBIg and antiviral therapy [75].
Treatment of recurrence after liver transplantation
There is no consensus about considering HBV recurrence as 
HBsAg or HBV DNA reappearance after LT. If untreated, HBV re-
currence can cause rapid development of severe liver dysfunc-
tion. The aim of therapy is to control HBV replication over time to 
prevent graft loss [75]. High-barrier NUCs provided good results 
for treatment of HBV recurrence; however, renal function has to 
be carefully evaluated. In this setting, ETV may be the preferred 
option, but attention should be paid to previous LAM therapies.
Use of suboptimal donors: Anti-HBc and HbsAg-positive 
donors
One of the major problems in the LT setting is the gap be-
tween patients in the waiting list and the donor pool. For this 
reason, suboptimal donors have been used to increase organs 
availability. Anti-HBc-positive donors are the most common 
suboptimal liver donors; the anti-HBc donor rate depends on 
HBV prevalence, being 5.5% in the USA, 10–15% in Europe, 
and 50% in Asia. Albeit in the absence of detectable serologi-
cal viremia, anti-HBc-positive subjects can have detectable vi-
remia in hepatocytes because of the ccc-DNA.
This replication could increase during immunodepression or 
immunosuppression states, as after LT. Thus, use of anti-HBc-
positive grafts represents the first cause of de novo HBV in-
fection after LT.
Yen et al. identified 90 cases of de novo HBV infection among 
194 recipients who did not receive antiviral prophylaxis. The 
majority of infections occurred in HBV non-immune recipients 
(82/107), but also in previously vaccinated recipients and in 
isolated anti-HBc recipients. No cases of de novo HBV infec-
tion were reported among naturally immune (anti-HBc anti-
HBs +ve) recipients [106].
Thus, evaluation of recipient’s HBV serology before LT is man-
datory. This risk has been estimated to be 0–5% in anti-HBs 
and anti-HBc-positive recipients, 10–18% in isolated anti-
HBc or anti-HBs positive ones, and 70–80% in HBV-naive re-
cipients [107].
Prophylaxis after LT is of paramount importance. Different 
therapeutic strategies have been used. The first approach was 
mono-prophylaxis with HBIg, which produced a reduction of 
de novo HBV of 31.6% in naive recipients and of 7% in HBc-
positive recipients [107]. Then, new therapeutic regimens com-
bining NUCs and HBIg, aiming to limit HBIg over-use and to 
prevent viral mutations, were proposed. New therapeutic op-
tions using HBIg and NUCs or NUCs alone mono-prophylax-
is have been proposed. In contrast to HBV +ve recipients, the 
addition of HBIG to NUCs did not confer higher protection to 
LAM alone in this cohort of patients [108]. A recent consensus 
stated that LAM is the treatment of choice as it is the most 
cost-effective for prophylaxis, while ETV/TDF therapies may 
also be considered in more selected cases [75,109].
HbsAg-positive donors are another category of suboptimal do-
nors used in recent decades, albeit in limited cases. In these 
donors with chronic HBV infection, liver biopsy is mandato-
ry to exclude significant liver damage (i.e., inflammation or fi-
brosis) [109,110].
A retrospective analysis of UNOS data reviewed the outcomes 
in 92 recipients who received HBsAg +ve grafts [111]. The au-
thors did not show any difference in patient or graft surviv-
al when compared to recipients of HBsAg –ve grafts. Yu et al. 
[70] followed up 23 recipients who received HBsAg +ve grafts 
and who underwent combination therapy (ETV + HBIg) after 
LT; the recurrence rate of HBV infection was 100% (23/23) 
but no HBV-related graft dysfunction nor death were found.
In addition, several studies underlined the importance of not 
using HBsAg +ve grafts in HDV recipients; in fact, the pres-
ence of HBsAg can lead to a rapid and severe HDV reactiva-
tion and reinfection [110,112].
Conclusions
Allocation criteria have been proposed for HbsAg-positive do-
nor grafts; they should be firstly allocated to HbsAg-positive 
recipients, then to those with serological evidence of previous 
contact with HBV, and as a last choice to naive HBV recipients 
requesting urgent LT [110]. All patients receiving an HbsAg-
positive graft need post-transplant combined prophylaxis with 
HBIg and NUCs. In addition, HBV DNA with or without HBsAg 
should be monitored every 3 months for 1 year and then ev-
ery 3–6 months indefinitely thereafter [109[.
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